Clinical Trial Details
| Trial ID: | L7060 |
| Source ID: | NCT02303405 |
| Associated Drug: | Hydroxychloroquine |
| Title: | Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | TERMINATED |
| Study Results: | YES |
| Results: | https://ClinicalTrials.gov/show/NCT02303405/results |
| Conditions: | Diabetes Mellitus Type 2 With Hyperglycemia |
| Interventions: | DRUG: Hydroxychloroquine|DRUG: Pioglitazone |
| Outcome Measures: | Primary: Hemoglobin A1c, Glycemic control, 4 months | Secondary: Fasting Plasma Glucose, Fasting glucose level, 4 months|Percent of Subjects Achieving HbA1c < 7.5%, Percent of subjects achieving a HbA1c level \< 7.5%, 4 months|Weight, Body weight, 4 months|Body Mass Index, Body mass index (BMI), 4 months|HOMA-IR, Insulin resistance by the HOMA model, 4 months|QUICKI, Insulin resistance by the QUICKI model, 4 months|Hs-CRP, Highly-sensitive C-reactive protein (inflammatory marker), 4 months|Leucocyte Count, White cell count (surrogate marker of inflammation), 4 months|Hypoglycemic Events, Number of hypoglycemic events, 4 months|Adverse Events, All other adverse events other than hypoglycemia, 4 months |
| Sponsor/Collaborators: | Sponsor: Charles Drew University of Medicine and Science |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE2 |
| Enrollment: | 22 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2014-11 |
| Completion Date: | 2017-11 |
| Results First Posted: | 2022-10-20 |
| Last Update Posted: | 2022-10-20 |
| Locations: | Charles Drew University of Medicine and Science, Los Angeles, California, 90059, United States |
| URL: | https://clinicaltrials.gov/show/NCT02303405 |
